WO2001078731A1 - Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree - Google Patents

Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree Download PDF

Info

Publication number
WO2001078731A1
WO2001078731A1 PCT/EP2001/004162 EP0104162W WO0178731A1 WO 2001078731 A1 WO2001078731 A1 WO 2001078731A1 EP 0104162 W EP0104162 W EP 0104162W WO 0178731 A1 WO0178731 A1 WO 0178731A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
active ingredient
infusion solutions
infusion
solutions according
Prior art date
Application number
PCT/EP2001/004162
Other languages
German (de)
English (en)
Inventor
Klaus Sommermeyer
Hans-Jörg Müller
Tilo Hniopek
Bernd Eschenbach
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Priority to EP01933818A priority Critical patent/EP1282422A1/fr
Priority to AU2001260198A priority patent/AU2001260198A1/en
Publication of WO2001078731A1 publication Critical patent/WO2001078731A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to infusion solutions of l-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (l-piperazinyl) -quinoline-3-carboxylic acid containing 0.015 to 0.5 g of the active ingredient mentioned per 100 ml aqueous solution and a sufficient amount of one or more physiologically acceptable acid (s) to dissolve the active ingredient and to stabilize the solution. Furthermore, the invention relates to the process of producing and using such infusion solutions.
  • the invention describes ready-to-use infusion solutions as well as other dosage forms which are introduced into such infusion solutions before application, the active ingredient being 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -quinoline-3-carboxylic acid is known as ciprofloxacin.
  • EP-A-0049 355 protects i.a. Medicines containing 7-amino-l-cyclopropyl-4-oxo-l, 4-dihydronaphtyridine-3-carboxylic acid.
  • EP-A-0 078 362 protects 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-quinoline-3-carboxylic acids.
  • the active ingredients known from the two EPs have high antibacterial effects and are therefore suitable as medicaments for combating bacterial infections in humans and animals.
  • the known compounds are not or only very little suitable for producing infusion and / or injection solutions because, for example, the pH value and / or the solubility and / or the shelf life, in particular with regard to excretions, of the ready-to-use infusion and / or injection solutions do not meet the pharmaceutical requirements for such solutions.
  • DE 33 33 719 AI discloses solutions of the lactic acid salts of piperazinyl-quinolonic and / or -azaquinolonecarboxylic acids which, in addition to the lactic acid salts mentioned and optionally conventional auxiliaries, additionally contain at least one acid which does not lead to precipitation.
  • acids which do not lead to precipitation include lactic acid, methanesulfonic acid, propionic acid or succinic acid, although lactic acid is by far preferred.
  • the lactic acid content of the infusion solutions according to DE 33 33 719 AI can carry 0.1 to 90%.
  • the lactic acid content of the solution to be applied can be 0.1 to 10%.
  • EP-A-0 219 784 The problems occurring according to DE 33 33 719 AI (corresponds to EP-A 0 138 018) are tried to be avoided by EP-A-0 219 784 by providing infusion solutions of ciprofloxacin which contain 0.015 to 0.5 g of the active ingredient per 100 ml of aqueous solution and, depending on the active substance concentration, 0.9 to 5.0 mol, based on 1 mol of active substance, of one or more physiologically tolerated acids.
  • the infusion solutions according to EP-A 0 219 784 contain, in addition to the active ingredient, water and other customary formulation auxiliaries, an amount of one or more acids from the group consisting of hydrochloric acid, methanesulfonic acid, propionic acid, succinic acid, glutaric acid, sufficient to dissolve the active ingredient and stabilize the solution.
  • hydrochloric acid methanesulfonic acid, propionic acid, succinic acid, glutaric acid
  • Citric acid fumaric acid, maleic acid, tartaric acid, glutamic acid, gluconic acid, glucuronic acid, galacturonic acid, ascorbic acid, phosphoric acid, adipic acid, hydroxyacetic acid, sulfuric acid, nitric acid, Acetic acid, malic acid, L-aspartic acid and lactic acid.
  • EP-A-0 287 926 relates to parenterally administrable solutions of quinolonecarboxylic acids, i.a. Ciprofloxacin, where it is proposed to use particularly pure main active ingredient components to improve storage stability.
  • EP-A-0 287 926 relates to those solutions which can be administered parenterally and in which no more than 1 to 10 ppm, based on the main active ingredient (ciprofloxacin) of the solution, are present on secondary components (“impurities” of the active ingredient)
  • impurities of the active ingredient
  • the publication DE 197 03 023 A discloses that the number of detectable particles is reduced by using glass bottles which have a silicone coating on the inner surface. This can further improve the shelf life of high-purity infusion solutions. It can therefore be assumed that the formation of precipitates is due to the number of particles that are inherently present. The more particles there are, the more particles are formed. This accelerates the formation of particles over time.
  • the mono- or diesters of orthophosphoric acid are compounds in which the alcohol component is glycerol or another higher-value physiologically compatible sugar such as glucose, sucrose, fructose or a higher-value physiologically compatible sugar alcohol such as sorbitol, mannitol or xylitol.
  • the alcohol component is glycerol or another higher-value physiologically compatible sugar such as glucose, sucrose, fructose or a higher-value physiologically compatible sugar alcohol such as sorbitol, mannitol or xylitol.
  • the acid to be used for stabilizing the infusion solutions of ciprofloxacin is particularly preferably glycerol esters of orthophosphoric acid. Are particularly preferred
  • Monoglycerinorthophosphorklareester Of very great interest are infusion solutions in which the acid (s) is glycerol 1 phosphate, glycerol 2 phosphate or a mixture of the glycerol phosphoric acid monoesters.
  • Diphosphates are also particularly suitable acids. These include in particular glucose diphosphate and fructose-1,6-diphosphate. The acids mentioned are about as strong as phosphoric acid.
  • additions of glycerol-1-phosphate, glycerol-2-phosphate, glucose diphosphate and / or fructose-1,6-diphosphate significantly outperform phosphoric acid in terms of improving storage stability.
  • the total amount of acid (s) can be significantly reduced.
  • An advantageous variant of the infusion solutions according to the invention is that the total content of the amount of acid (s) is below 1.04 moles based on 1 mole of active ingredient.
  • the total amount of acid can be reduced even further.
  • a further preferred embodiment according to the invention is characterized in that the infusion solution has a total acid content of less than 0.96 mol per 1 mol of active ingredient.
  • the minimum amount of acid required per mole of active ingredient to dissolve naturally also depends on the active ingredient concentration and the acid (s) used and is therefore not constant. It should also be noted that the information in the amounts of acid relates only to the amounts that are not converted into the corresponding salt (s) by adding bases according to generally known basic chemical rules. Dissociation of the acids was not taken into account in the quantities, so that they relate to the dissociated and undissociated amount of acid.
  • the infusion solutions according to the invention can also contain further formulation agents such as complexing agents, antioxidants, isotonizing agents and / or agents for adjusting the pH.
  • the osmolality of the infusion solutions is 0.20 to 0.70 Osm / kg, preferably 0.26 to 0.39 Osm / kg and is adjusted by isotonic agents such as NaCl, mannitol, glucose, sucrose and glycerol or mixtures of such substances. If necessary, substances can also be used that are contained in common, commercially available infusion carrier solutions.
  • the usual infusion carrier solutions include infusion solutions with an electrolyte supply without carbohydrates such as saline, Ringer's lactate solution and others, and those with carbohydrates and solutions for the supply of amino acids, each with and without carbohydrate content.
  • infusion carrier solutions are in Rote Liste 1998, list of finished medicinal products of the members of the Federal Association of the Pharmaceutical Industry eV, Editio Cantor, Aulendorf / Württ. listed.
  • the infusion solutions according to the invention have a pH of 3.0 to 5.2. pH values of 3.6 to 4.7 and 3.9 to 4.5 are preferred. PH values in the range from 4.1 to 4.3 are very particularly preferred.
  • the infusion solutions according to the invention can be present in dosage units suitable for infusion with removable contents of 40 to 600 ml, preferably 50 to 120 ml.
  • the present invention also relates to a process for the preparation of infusion solutions according to the independent claim relating to the infusion solutions, which is characterized in that a suitable amount of the active ingredient, optionally in the form of a salt such as alkali or alkaline earth metal salt or addition salt, a hydrate or a hydrate of the salt or in the form of mixtures of these salts or hydrates, with an amount of a physiologically tolerable monoester or diester of orthophosphoric acid or a mixture of several physiologically tolerable monoester or diester derivatives of orthophosphoric acid, which is preferably less than 1.04 mol per mol of active ingredient , if necessary, adding formulation auxiliaries and making up with water or a conventional infusion carrier solution in such a way that a concentration range of 0.015 to 0.5 g for the active ingredient, whereby when using an alkali or alkaline earth metal salt of the active ingredient, the amounts required for dissolution are additionally contained in the amounts necessary for neutralizing the active ingredient anion and, when using
  • the solutions correspond to the properties already listed with regard to pH, amounts of acid and osmolality. If the active ingredient is used in salt form, it is expedient to use an acid whose anion corresponds to the anion of the active ingredient salt or of the salt hydrate.
  • the pH of the infusion solutions according to the invention can be adjusted to the above-mentioned values with (physiologically) compatible acids and / or bases, i.e. Set 3.0 to 5.2, especially 3.6 to 4.7.
  • the solutions or only a part thereof can be heated slightly, preferably to temperatures between 20 ° C and 80 ° C.
  • the solutions according to the invention can be produced particularly economically via concentrated solutions.
  • the amounts of active ingredient required for a batch with the main amount of acid required for the batch e.g. 95% based on molar basis
  • This concentrate is then diluted.
  • any other auxiliary substances - such as Table salt for isotonization - added, as well as the possibly still missing amount of acid.
  • the solutions according to the invention show a high storage stability, which is not limited by the number of particles.
  • the effort as described in documents EP 0 287 926 and DE-A-197 30 23 to make the solutions durable can be dispensed with.
  • the solution thus obtained was filtered, placed in a glass bottle for medical purposes and then sterilized at 121 ° C.
  • the sterile solution thus obtained was stored at room temperature for 6 months and regularly checked visually. No changes were visually observed after this period.
  • the subvisual particles determined by the usual method of light blocking, were low and also remained unchanged. They met the special requirements of the pharmacopoeia for such solutions.
  • Example 1 was essentially repeated. However, the solution obtained was not filled into a glass bottle but into a polyolefin-based bag, which is also suitable for medical purposes. No changes were visually observed after storage for 6 months.
  • the solution thus obtained was filtered like Example 1, filled into a glass bottle for medical purposes and then sterilized at 121 ° C.
  • the sterile solution thus obtained was stored at room temperature for 2 months and regularly checked visually. After two months there was a visually detectable crystal formation. The attempt was then stopped.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des solutions de perfusion d'acide 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pipérazinyl)-quinoline-3-carboxylique (ciprofloxacine), qui contiennent 0,015 à 0,5 g du principe actif pour 100 ml de solution aqueuse et une quantité suffisante pour la dissolution du principe actif et la stabilisation de la solution d'un ou de plusieurs acides physiologiquement acceptables. Les solutions selon l'invention sont caractérisées en ce que l'acide ou les acides sont un ou plusieurs monoesters ou diesters de l'acide orthophosphorique. Les solutions de perfusion selon l'invention sont stables au stockage malgré une teneur en acide faible.
PCT/EP2001/004162 2000-04-15 2001-04-11 Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree WO2001078731A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01933818A EP1282422A1 (fr) 2000-04-15 2001-04-11 Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree
AU2001260198A AU2001260198A1 (en) 2000-04-15 2001-04-11 Ciprofloxacin infusion solutions with improved storage life

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018781A DE10018781A1 (de) 2000-04-15 2000-04-15 Infusionslösungen des Ciprofloxacins mit verbesserter Lagerfähigkeit
DE10018781.1 2000-04-15

Publications (1)

Publication Number Publication Date
WO2001078731A1 true WO2001078731A1 (fr) 2001-10-25

Family

ID=7638902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004162 WO2001078731A1 (fr) 2000-04-15 2001-04-11 Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree

Country Status (4)

Country Link
EP (1) EP1282422A1 (fr)
AU (1) AU2001260198A1 (fr)
DE (1) DE10018781A1 (fr)
WO (1) WO2001078731A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026233A1 (fr) * 2000-09-29 2002-04-04 Fresenius Kabi Deutschland Gmbh Solution pour perfusion de ciprofloxacine stable au stockage et a teneur reduite en acide
DE102004005186B3 (de) * 2004-02-02 2005-10-13 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von gereinigtem Ciprofloxacin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101185A2 (fr) * 1982-07-20 1984-02-22 SHIMIZU SEIYAKU KABUSHIKI KAISHA also known as Shimizu Pharmaceutical Co., Ltd. Composition de transfusion pour infusion par voie intraveineuse
US5334589A (en) * 1989-12-29 1994-08-02 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
DE19730023A1 (de) * 1997-07-11 1999-01-14 Bayer Ag Hochreine Ciprofloxacin-Infusion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60261252A (ja) * 1984-06-08 1985-12-24 Dainippon Screen Mfg Co Ltd 画像信号の密度変換方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101185A2 (fr) * 1982-07-20 1984-02-22 SHIMIZU SEIYAKU KABUSHIKI KAISHA also known as Shimizu Pharmaceutical Co., Ltd. Composition de transfusion pour infusion par voie intraveineuse
US5334589A (en) * 1989-12-29 1994-08-02 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
DE19730023A1 (de) * 1997-07-11 1999-01-14 Bayer Ag Hochreine Ciprofloxacin-Infusion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FAOUZI, M. A. ET AL: "Stability and compatibility studies of pefloxacin, ofloxacin and ciprofloxacin with PVC infusion bags", INT. J. PHARM. (1993), 89(2), 125-31, XP001008191 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026233A1 (fr) * 2000-09-29 2002-04-04 Fresenius Kabi Deutschland Gmbh Solution pour perfusion de ciprofloxacine stable au stockage et a teneur reduite en acide
DE102004005186B3 (de) * 2004-02-02 2005-10-13 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von gereinigtem Ciprofloxacin

Also Published As

Publication number Publication date
EP1282422A1 (fr) 2003-02-12
DE10018781A1 (de) 2001-10-25
AU2001260198A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
DE3240177C2 (fr)
EP1206281B1 (fr) Formulation comprenant moxifloxacin et chlorure de sodium
DE602005002495T2 (de) Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat
WO2001078732A1 (fr) Solution pour perfusion stable au stockage a base de ciprofloxacine
EP0661060A2 (fr) Composition d'immunoglobuline de haute concentration et procédé de sa préparation
DE3333719A1 (de) Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
DE60025627T2 (de) Pharmazeutische lösung von levosimendan
EP1255557B1 (fr) Preparation pharmaceutique stable, pouvant etre utilisee par voie nasale, orale ou sublinguale contenant de la desmopressine
AT397462B (de) Wässerige piroxicamlösungen
EP1206244B1 (fr) Composition pharmaceutique aqueuse a base de moxifloxacine ou de ses sels
EP0806955B1 (fr) Solutions d'injection ou de perfusion d'enrofloxacine
EP0656780B1 (fr) Medicaments contenant des acides diphosphoniques et leurs sels
DE3000743A1 (de) Arzneipraeparat auf der basis eines salzes der acetylsalicylsaeure und einer basischen aminosaeure und verfahren zu seiner herstellung
EP0435826A1 (fr) Solutions intraveineuses pour l'épilepsie
DE3119510C2 (fr)
WO2002026233A1 (fr) Solution pour perfusion de ciprofloxacine stable au stockage et a teneur reduite en acide
DE60101979T2 (de) Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel
EP0591710B1 (fr) Solutions injectable contenant du mesna
EP1073469B1 (fr) Solutions stables de mitoxantrone
WO2001078731A1 (fr) Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree
EP1807112B1 (fr) Preparations aqueuses stables d'un derive de platine
DE2546474A1 (de) Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung
CH654744A5 (de) Waessrige pharmazeutische formulierung auf basis eines vincaalkaloids.
DE2461570C3 (de) Arzneimittel für die Behandlung bakterieller Infektionen der Augen und/oder der Ohren und Verfahren zu ihrer Herstellung
EP0656777B1 (fr) Solutions d'azosemide a injecter, pretes a l'emploi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001933818

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001933818

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001933818

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP